- Medtronic narrowed its full-year adjusted EPS guidance to a range of $5.44 to $5.50 from the previous range of $5.42 to $5.50, with estimates at $5.45.
- The company raised its FY25 organic revenue growth target to between 4.75% and 5%, up from the previous range of 4.5% to 5%.
- Second-quarter revenue increased to $8.40 billion, reflecting a 5.2% year-over-year growth, surpassing the estimate of $8.27 billion.
- Cardiovascular revenue reached $3.10 billion, a 6.1% rise from the previous year, exceeding the estimate of $3.06 billion.
- Medical Surgical revenue slightly declined by 0.7% year-over-year to $2.13 billion, just below the estimate of $2.14 billion.
- Neuroscience revenue grew by 7.1% year-over-year to $2.45 billion, beating the estimate of $2.4 billion.
- Diabetes revenue saw a significant increase of 12% year-over-year, reaching $686 million, above the estimated $662.3 million.
- The company’s FY25 diluted non-GAAP EPS growth is expected to be in the range of 4.6% to 5.8%.
- Medtronic is optimistic about continued diversified growth, emphasizing the strength of its pipeline in high-impact markets to benefit more patients globally.
- Analyst recommendations for Medtronic include 16 buys, 16 holds, and 2 sells.
“`
Medtronic Plc on Smartkarma
Independent analysts on Smartkarma like Baptista Research are closely covering Medtronic Plc, a renowned company in the medical technology sector. Baptista Research recently published reports on Medtronic’s fiscal performances, highlighting sustained growth and strategic advancements. In one report titled “Medtronic plc: Are Its Investments in Robotics with Hugo Robotic-Assisted Surgery System Yielding Results? – Major Drivers,” the analysts mention strong revenue growth of 5.3% driven by key segments like Cardiovascular, Neuroscience, and Diabetes. The report emphasizes Medtronic’s product innovations and global market expansions as contributing factors to its success.
In another insightful report named “Medtronic plc: Expansion Of Global Operations & Supply Chain Transformation! – Major Drivers,” Baptista Research discusses Medtronic’s fiscal year 2024 Q4 earnings, showcasing significant revenue growth exceeding 5% for the full year. The analysts praise Medtronic’s effective strategies in driving growth and profitability, particularly through new product innovations across various therapeutic segments. These reports provide investors with valuable insights into Medtronic’s performance and potential, affirming the company’s position as a strong player in the medical technology industry.
A look at Medtronic Plc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Medtronic Plc, a company developing therapeutic and diagnostic medical products, has received above-average scores in Dividend and Momentum, indicating a positive long-term outlook. With a strong focus on maintaining shareholder returns through dividends and showing positive momentum in the market, Medtronic is poised to attract investors looking for stable returns and growth potential. While Value, Growth, and Resilience scores are average, the company’s emphasis on dividends and current market performance bode well for its future prospects.
Overall, Medtronic Plc‘s Smart Scores paint a picture of a company that may provide consistent dividends and show promising market momentum in the long run. Coupled with its wide array of medical products sold globally, Medtronic’s strengths in dividend payouts and market performance could position it as a favorable investment choice for those seeking both income and growth opportunities in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
